Table 4 Univariable and multivariable survival analysis with immune metagenes and conventional variables in the high proliferation tertile.
From: Interactions between immunity, proliferation and molecular subtype in breast cancer prognosis
PH(n= 421) | Univariable | Multivariable | ||
|---|---|---|---|---|
Variables | Hazard ratio (95% CI)7 | P- value8 | Hazard ratio (95% CI) | P- value |
B/P (L, I, H)1 | 0.55 (0.45 to 0.66) | < 0.0001 | 0.59 (0.45 to 0.78) | 0.0001 |
M/D (L, I, H) | 0.62 (0,51 to 0.75) | < 0.0001 | 0.89 (0.65 to 1.21) | 0.45 |
T/NK (L, I, H) | 0.62 (0.51 to 0.75) | < 0.0001 | 0.98 (0.71 to 1.35) | 0.9 |
LN Status (-,+)2 | 1.38 (0.99 to 1.94) | 0.06 | 1.75 (1.12 to 2.74) | 0.01 |
Tumor Size (T1, T2, T3)3 | 1.37 (1.02 to 1.85) | 0.04 | 1.44 (1.05 to 1.97) | 0.02 |
Histologic Grade (1,2,3)4 | 0.72 (0.54 to 0.95) | 0.02 | 0.80 (0.59 to 1.08) | 0.14 |
Age (≤ 40 yrs, > 40 yrs)5 | 1.26 (0.83 to 1.91) | 0.28 | 1.19 (0.73 to 1.72) | 0.61 |
ER Status (+,-)6 | 0.68 (0.49 to 0.96) | 0.03 | 0.87 (0.60 to 1.26) | 0.46 |
Systemic Treatment (no, yes) | 1.02 (0.74 to 1.41) | 0.89 | 1.56 (1.02 to 2.39) | 0.04 |